MedTrace Logo

Ultra-low Dose Bevacizumab Plus Temozolomide for Recurrent High-grade Gliomas

NCT02416999 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2016-02-18

No results posted yet for this study

Summary

This study is to evaluate the effectiveness of ultra-low dose Bevacizumab plus Temozolomide for recurrent high-grade gliomas.

Conditions

  • Recurrent High-grade Glioma

Interventions

DRUG

Ultra-low dose Bevacizumab

DRUG

Temozolomide

Sponsors & Collaborators

  • Beijing Tiantan Hospital

    collaborator OTHER

  • Hebei Yanda Hospital

    lead OTHER

Principal Investigators

  • Jisheng Wang, MD · Beijing Tiantan Hospital

  • Nan Ji, MD · Beijing Tiantan Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-05-31
Primary Completion
2018-05-31
Completion
2018-05-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02416999 on ClinicalTrials.gov